J. Wesley Fox, Ph.D. is the President and CEO of NephroGenex. Dr. Fox has over 20 years of experience in the healthcare industry and has led the organization, funding and management of several biotechnology companies. He is a co-founder of NephroGenex, BioStratum, EnzyMed (acquired by Albany Molecular Research), and RiboGene, Inc. (merged to form Questcor Pharmaceuticals). Dr. Fox is also a member of the board of directors of BioLamina. Prior to co-founding NephroGenex, Dr. Fox was co-founder and Chief Scientific Officer of BioStratum, Inc., where he established and directed the company's research and development operations that identified the company's lead product candidate for diabetic kidney disease (Pyridorin™), a drug candidate for cancer, and recombinant laminins for stem cell technology. Dr. Fox has also held research and development positions with Idexx Laboratories and Abbott Laboratories.

Bob has over 25 years of product development experience in the pharmaceutical and cardiovascular implant industry. Prior to joining NephroGenex, Bob spent 8 years as Director of Product Development for BioStratum Inc. where he led the development of biopharmaceutical candidates from concept to early clinical trials. In the field of cardiovascular implants, Bob worked for CardioPolymers Inc. overseeing development of novel biopolymer therapy for the treatment of chronic heart failure. He also worked at Baxter International where he led the development from concept to market release of a complete line of ePTFE vascular grafts for peripheral use, and a complete line of endovascular prosthetic grafts for treatment of abdominal aortic aneurysms. Prior to the pharmaceutical and medical device industries, Bob served as an officer in the United States Army. Bob graduated from the United States Military Academy at West Point and received his Master of Engineering Degree at the University of California, Berkeley.